ProShare Advisors
SRNE

ProShare Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

ProShare Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-59,354
Closed -$52.6K – 1942
2022
Q4 		$52.6K Buy
59,354
+17,443
+42% +$23.1K ﹤0.01% 1734
2022
Q3 		$66K Sell
41,911
-801
-2% -$1.82K ﹤0.01% 1627
2022
Q2 		$86K Sell
42,712
-13,302
-24% -$23K ﹤0.01% 1633
2022
Q1 		$131K Sell
56,014
-9,251
-14% -$28.9K ﹤0.01% 1983
2021
Q4 		$303K Buy
65,265
+29,662
+83% +$184K ﹤0.01% 1782
2021
Q3 		$272K Sell
35,603
-35,127
-50% -$298K ﹤0.01% 1616
2021
Q2 		$685K Buy
70,730
+3,844
+6% +$30.6K ﹤0.01% 1289
2021
Q1 		$553K Buy
66,886
+11,437
+21% +$121K ﹤0.01% 1372
2020
Q4 		$378K Buy
55,449
+28,313
+104% +$227K ﹤0.01% 1447
2020
Q3 		$303K Buy
27,136
+3,303
+14% +$30.2K ﹤0.01% 1168
2020
Q2 		$150K Buy
+23,833
New +$91.2K ﹤0.01% 1520
2020
Q1 		– Sell
-16,961
Closed -$57K – 1678
2019
Q4 		$57K Buy
16,961
+2,709
+19% +$6.46K ﹤0.01% 1741
2019
Q3 		$30K Buy
14,252
+2,118
+17% +$4.94K ﹤0.01% 1633
2019
Q2 		$32K Sell
12,134
-318
-3% -$1.14K ﹤0.01% 1595
2019
Q1 		$59K Buy
12,452
+934
+8% +$2.45K ﹤0.01% 1606
2018
Q4 		$28K Sell
11,518
-1,857
-14% -$6.06K ﹤0.01% 1544
2018
Q3 		$59K Buy
13,375
+1,924
+17% +$10.7K ﹤0.01% 1713
2018
Q2 		$82K Buy
+11,451
New +$77.9K ﹤0.01% 1729

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

ProShare Advisors's SRNE Position: Q1 2023 in Review

ProShare Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 59,354 shares — an estimated $52.6K sold.

ProShare Advisors first reported a position in SRNE in Q2 2018 and held it in 18 quarters. The position peaked at $685K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • ProShare Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • ProShare Advisors sold 59,354 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $52.6K.
  • ProShare Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 18 quarters.
  • ProShare Advisors's Sorrento Therapeutics, Inc. position peaked at $685K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on ProShare Advisors's 13F filing for Q1 2023, filed 12 May 2023.